Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Are These Four Stocks in The Spotlight Today?

Cal-Maine Foods Inc (NASDAQ:CALM) shares were off more than 6% today before rallying to green territory in morning trading after the shell egg producer reported its latest quarterly results. For its second quarter, the company reported EPS of $2.26 on revenue of $546 million, missing estimates by $0.14 per share and $6.31 million. Cal-Maine Foods Inc (NASDAQ:CALM) results were lower than expected mostly because of weaker egg pricing and higher feed costs. CEO Dolph Baker said:

“Our industry continues to deal with the significant reduction in the national laying hen flock that occurred this past spring related to the Avian Influenza (AI) outbreaks in the upper Midwestern United States. While the supply is gradually starting to move back up, the current national laying hen flock reported by the USDA yesterday is still approximately nine percent lower than it was a year ago. Egg prices have moved lower than expected in spite of the reduced supply, and we expect prices will remain volatile until the industry has more clarity on future supply levels.”

Following the report, the analysts at D.A. Davidson trimmed their price target to $60 from $65 but said they would be buyers on weakness, as they like Cal-Maine’s planned increase in specialty egg production, which should increase prices in the long run.

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) is 2.4% higher in morning trading as momentum from yesterday’s good news pushes the stock forward. On Wednesday, Adamas Pharmaceuticals Inc (NASDAQ:ADMS) announced that its lead product candidate, ADS-5102 (amantadine HCl), had successfully met the primary endpoint in a phase 3 clinical trial concerning its safety and efficacy for the treatment of levodopa-induced dyskinesia in Parkinson’s disease patients. Adamas will present a more comprehensive version of the data gleaned from the trial at an upcoming scientific conference. A total of 15 funds from our database, including Jim Simons’ Renaissance Technologies, owned 12.5% of the company’s float at the end of September.

Follow Cal-Maine Foods Inc (NASDAQ:CALM)
Trade (NASDAQ:CALM) Now!

Follow Adamas Pharmaceuticals Inc (NASDAQ:ADMS)
Trade (NASDAQ:ADMS) Now!

Disclosure: none

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.